Targeting Fas in osteoresorptive disorders

Expert Opinion on Therapeutic Targets

Volumn 14, Issue 10, 2010, Pages 1121-1134

  Kovacic, Natasa ^a   Grcevic, Danka ^a   Katavic, Vedran ^a   Lukic, Ivan Kresimir ^b,c   Marusic, Ana ^b  

^a UNIVERSITY OF ZAGREB   (Croatia)

^b UNIVERSITY OF SPLIT   (Croatia)

^c Biosistemi   (Croatia)

Author keywords

CD95; Osteoblast; Osteoclast; Osteoresorption

Indexed keywords

ACETYLSALICYLIC ACID; CASPASE 9; FAS ANTIGEN; FAS LIGAND; IKARISOSIDE A; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; NATURAL PRODUCT; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEIN BID; RAF PROTEIN; SMAD PROTEIN; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG; WNT PROTEIN;

APOPTOSIS; BONE CELL; BONE DENSITY; CELL DIFFERENTIATION; CELL LINEAGE; DRUG TARGETING; ESTROGEN DEFICIENCY; GENE EXPRESSION; HUMAN; IN VITRO STUDY; INFLAMMATION; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PATHOGENESIS; REVIEW; SIGNAL TRANSDUCTION; TISSUE SPECIFICITY;

ANIMALS; ANTIGENS, CD95; APOPTOSIS; BONE AND BONES; BONE RESORPTION; CELL DIFFERENTIATION; CELL LINEAGE; FAS LIGAND PROTEIN; GENE EXPRESSION; HUMANS; MOLECULAR TARGETED THERAPY; OSTEOBLASTS; OSTEOCLASTS; OSTEOGENESIS; SIGNAL TRANSDUCTION;

EID: 77957084928     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.2010.522347     Document Type: Review

References (112)

1. French LE, Hahne M, Viard I, et al. Fas and Fas ligand in embryos and adult mice: ligand expression in several immune-privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover. J Cell Biol 1996;133(2):335-343
2. Guicciardi ME, Gores GJ. Life and death by death receptors. FASEB J 2009;23(6):1625-1637
3. Sharma K, Wang RX, Zhang LY, et al. Death the Fas way: regulation and pathophysiology of CD95 and its ligand. Pharmacol Ther 2000;88(3):333-347
4. Itoh N, Nagata S. A novel protein domain required for apoptosis. Mutational analysis of human Fas antigen. J Biol Chem 1993;268(15):10932-10937.
5. Cheng J, Zhou T, Liu C, et al. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 1994;263(5154):1759-1762
6. Aggarwal BB. Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol 2003;3(9):745-756.
7. Suda T, Takahashi T, Golstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993;75(6):1169-1178.
8. Barry M, Bleackley RC. Cytotoxic T lymphocytes: all roads lead to death. Nat Rev Immunol 2002;2(6):401-409
9. Griffith TS, Brunner T, Fletcher SM, et al. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 1995;270(5239):1189-1192
10. Hohlbaum AM, Moe S, Marshak-Rothstein A. Opposing effects of transmembrane and soluble Fas ligand expression on inflammation and tumor cell survival. J Exp Med 2000;191(7):1209-1220
11. Ramaswamy M, Cleland SY, Cruz AC, Siegel RM. Many checkpoints on the road to cell death: regulation of Fas-FasL interactions and Fas signaling in peripheral immune responses. Results Probl Cell Differ 2009;49:17-47
12. Yu KY, Kwon B, Ni J, et al. A newly identified member of tumor necrosis factor receptor superfamily (TR6) suppresses LIGHT-mediated apoptosis. J Biol Chem 1999;274(20):13733-13736
13. Sun M, Ames KT, Suzuki I, Fink PJ. The cytoplasmic domain of Fas ligand costimulates TCR signals. J Immunol 2006;177(3):1481-1491
14. Sancho-Martinez I, Martin-Villalba A. Tyrosine phosphorylation and CD95: a FAScinating switch. Cell Cycle 2009;8(6):838-842
15. Dempsey PW, Doyle SE, He JQ, Cheng G. The signaling adaptors and pathways activated by TNF superfamily. Cytokine Growth Factor Rev 2003;14(3-4):193-209
16. Strasser A, Jost PJ, Nagata S. The many roles of FAS receptor signaling in the immune system. Immunity 2009;30(2):180-192.
17. Lavrik I, Golks A, Krammer PH. Death receptor signaling. J Cell Sci 2005;118(Pt 2):265-267
18. Mahmood Z, Shukla Y. Death receptors: targets for cancer therapy. Exp Cell Res 2010;316(6):887-899
19. Pallasch CP, Wendtner CM. Overexpression of the Fas-inhibitory molecule TOSO: a novel antiapoptotic factor in chronic lymphocytic leukemia. Leuk Lymphoma 2009;50(3):498-501.
20. Muppidi JR, Tschopp J, Siegel RM. Life and death decisions: secondary complexes and lipid rafts in TNF receptor family signal transduction. Immunity 2004;21(4):461-465
21. Hamad AR. Analysis of gene profile, steady state proliferation and apoptosis of double-negative T cells in the periphery and gut epithelium provides new insights into the biological functions of the Fas pathway. Immunol Res 2010;47(1-3):134-142
22. Dhein J, Walczak H, Baumler C, et al. Autocrine T-cell suicide mediated by APO-1/(Fas/CD95). Nature 1995;373(6513):438-441
23. Ingulli E, Mondino A, Khoruts A, Jenkins MK. In vivo detection of dendritic cell antigen presentation to CD4(+) T cells. J Exp Med 1997;185(12):2133-2141
24. Villena SN, Pinheiro RO, Pinheiro CS, et al. Capsular polysaccharides galactoxylomannan and glucuronoxylomannan from Cryptococcus neoformans induce macrophage apoptosis mediated by Fas ligand. Cell Microbiol 2008;10(6):1274-1285
25. Krammer PH. CD95s deadly mission in the immune system. Nature 2000;407(6805):789-795
26. Mori T, Ando K, Tanaka K, et al. Fas-mediated apoptosis of the hematopoietic progenitor cells in mice infected with murine cytomegalovirus. Blood 1997;89(10):3565-3573
27. Screpanti V, Wallin RP, Grandien A, Ljunggren HG. Impact of FASL-induced apoptosis in the elimination of tumor cells by NK cells. Mol Immunol 2005;42(4):495-499
28. Gorbachev AV, Fairchild RL. CD4+ T cells regulate CD8+ T cell-mediated cutaneous immune responses by restricting effector T cell development through a Fas ligand-dependent mechanism. J Immunol 2004;172(4):2286-2295
29. Giroux M, Denis F. CD1d-unrestricted human NKT cells release chemokines upon Fas engagement. Blood 2005;105(2):703-710
30. Rescigno M, Piguet V, Valzasina B, et al. Fas engagement induces the maturation of dendritic cells (DCs), the release of interleukin (IL)-1beta, and the production of interferon gamma in the absence of IL-12 during DC-T cell cognate interaction: a new role for Fas ligand in inflammatory responses. J Exp Med 2000;192(11):1661-1668
31. Josefsen D, Myklebust JH, Lynch DH, et al. Fas ligand promotes cell survival of immature human bone marrow CD34 +CD38- hematopoietic progenitor cells by suppressing apoptosis. Exp Hematol 1999;27(9):1451-1459
32. Barcena A, Muench MO, Song KS, et al. Role of CD95/Fas and its ligand in the regulation of the growth of human CD34(++)CD38(-) fetal liver cells. Exp Hematol 1999;27(9):1428-1439
33. Kleber S, Sancho-Martinez I, Wiestler B, et al. Yes and PI3K bind CD95 to signal invasion of glioblastoma. Cancer Cell 2008;13(3):235-248
34. Barnhart BC, Legembre P, Pietras E, et al. CD95 ligand induces motility and invasiveness of apoptosis-resistant tumor cells. EMBO J 2004;23(15):3175- 3185
35. Neumann L, Pforr C, Beaudouin J, et al. Dynamics within the CD95 death-inducing signaling complex decide life and death of cells. Mol Syst Biol 2010;6:352
36. Frelin C, Imbert V, Bottero V, et al. Inhibition of the NF-kappaB survival pathway via caspase-dependent cleavage of the IKK complex scaffold protein and NF-kappaB essential modulator NEMO. Cell Death Differ 2008;15(1):152-160.
37. Desbarats J, Birge RB, Mimouni-Rongy M, et al. Fas engagement induces neurite growth through ERK activation and p35 upregulation. Nat Cell Biol 2003;5(2):118-125
38. Tourian L Jr, Zhao H, Srikant CB. p38alpha, but not p38beta, inhibits the phosphorylation and presence of c-FLIPS in DISC to potentiate Fas-mediated caspase-8 activation and type I apoptotic signaling. J Cell Sci 2004;117(Pt 26):6459-6471
39. Djouad F, Jackson WM, Bobick BE, et al. Activin A expression regulates multipotency of mesenchymal progenitor cells. Stem Cell Res Ther 2010;1(2):11
40. Grcevic D, Lukic IK, Kovacic N, et al. Activated T lymphocytes suppress osteoclastogenesis by diverting early monocyte/macrophage progenitor lineage commitment towards dendritic cell differentiation through down-regulation of receptor activator of nuclear factor-kappaB and c-Fos. Clin Exp Immunol 2006;146(1):146-158
41. Bu R, Borysenko CW, Li Y, et al. Expression and function of TNF-family proteins and receptors in human osteoblasts. Bone 2003;33(5):760-770
42. Lepri E, Delfino DV, Migliorati G, et al. Functional expression of Fas on mouse bone marrow stromal cells: upregulation by tumor necrosis factor-alpha and interferon-gamma. Exp Hematol 1998;26(13):1202-1208
43. Wu X, McKenna MA, Feng X, et al. Osteoclast apoptosis: the role of Fas in vivo and in vitro. Endocrinology 2003;144(12):5545-5555
44. Qiao C, Xu W, Zhu W, et al. Human mesenchymal stem cells isolated from the umbilical cord. Cell Biol Int 2008;32(1):8-15
45. Wieczorek G, Steinhoff C, Schulz R, et al. Gene expression profile of mouse bone marrow stromal cells determined by cDNA microarray analysis. Cell Tissue Res 2003;311(2):227-237
46. Kawakami A, Eguchi K, Matsuoka N, et al. Fas and Fas ligand interaction is necessary for human osteoblast apoptosis. J Bone Miner Res 1997;12(10):1637-1646.
47. Ozeki N, Mogi M, Nakamura H, Togari A. Differential expression of the Fas-Fas ligand system on cytokine-induced apoptotic cell death in mouse osteoblastic cells. Arch Oral Biol 2002;47(7):511-517
48. Kovacic N, Lukic IK, Grcevic D, et al. The Fas/Fas ligand system inhibits differentiation of murine osteoblasts but has a limited role in osteoblast and osteoclast apoptosis. J Immunol 2007;178(6):3379-3389
49. Kawakami A, Nakashima T, Tsuboi M, et al. Insulin-like growth factor I stimulates proliferation and Fas-mediated apoptosis of human osteoblasts. Biochem Biophys Res Commun 1998;247(1):46-51
50. Duque G, El Abdaimi K, Henderson JE, et al. Vitamin D inhibits Fas ligand-induced apoptosis in human osteoblasts by regulating components of both the mitochondrial and Fas-related pathways. Bone 2004;35(1):57-64
51. Jilka RL, Weinstein RS, Bellido T, et al. Osteoblast programmed cell death (apoptosis): modulation by growth factors and cytokines. J Bone Miner Res 1998;13(5):793-802
52. Roux S, Lambert-Comeau P, Saint-Pierre C, et al. Death receptors, Fas and TRAIL receptors, are involved in human osteoclast apoptosis. Biochem Biophys Res Commun 2005;333(1):42-50
53. Ogawa Y, Ohtsuki M, Uzuki M, et al. Suppression of osteoclastogenesis in rheumatoid arthritis by induction of apoptosis in activated CD4+ T cells. Arthritis Rheum 2003;48(12):3350-3358
54. Park H, Jung YK, Park OJ, et al. Interaction of Fas ligand and Fas expressed on osteoclast precursors increases osteoclastogenesis. J Immunol 2005;175(11):7193-7201
55. Nakamura T, Imai Y, Matsumoto T, et al. Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts. Cell 2007;130(5):811-823
56. Wu X, Pan G, McKenna MA, et al. RANKL regulates Fas expression and Fas-mediated apoptosis in osteoclasts. J Bone Miner Res 2005;20(1):107-116 (Pubitemid 41716225)
57. Krum SA, Miranda-Carboni GA, Hauschka PV, et al. Estrogen protects bone by inducing Fas ligand in osteoblasts to regulate osteoclast survival. EMBO J 2008;27(3):535-545
58. Kitaura H, Nagata N, Fujimura Y, et al. Effect of IL-12 on TNF-alpha-mediated osteoclast formation in bone marrow cells: apoptosis mediated by Fas/Fas ligand interaction. J Immunol 2002;169(9):4732-4738
59. Yoshimatsu M, Kitaura H, Fujimura Y, et al. IL-12 inhibits TNF-alpha induced osteoclastogenesis via a T cell-independent mechanism in vivo. Bone 2009;45(5):1010-1016
60. Takahashi T, Tanaka M, Brannan CI, et al. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell 1994;76(6):969-976
61. Roths JB, Murphy ED, Eicher EM. A new mutation, gld, that produces lymphoproliferation and autoimmunity in C3H/HeJ mice. J Exp Med 1984;159(1):1-20
62. Ramsdell F, Seaman MS, Miller RE, et al. gld/gld mice are unable to express a functional ligand for Fas. Eur J Immunol 1994;24(4):928-933
63. Watanabe-Fukunaga R, Brannan CI, Itoh N, et al. The cDNA structure, expression, and chromosomal assignment of the mouse Fas antigen. J Immunol 1992;148(4):1274-1279
64. Murphy ED, Roths JB. Lymphoproliferation (lpr). Mouse News Lett 1978;58:47
65. Allen RD, Marshall JD, Roths JB, Sidman CL. Differences defined by bone marrow transplantation suggest that lpr and gld are mutations of genes encoding an interacting pair of molecules. J Exp Med 1990;172(5):1367-1375
66. Mariani SM, Matiba B, Armandola EA, Krammer PH. The APO-1/Fas (CD95) receptor is expressed in homozygous MRL/lpr mice. Eur J Immunol 1994;24(12):3119-3123
67. Hahne M, Peitsch MC, Irmler M, et al. Characterization of the non-functional Fas ligand of gld mice. Int Immunol 1995;7(9):1381-1386
68. Adachi M, Suematsu S, Kondo T, et al. Targeted mutation in the Fas gene causes hyperplasia in peripheral lymphoid organs and liver. Nat Genet 1995;11(3):294-300.
69. Karray S, Kress C, Cuvellier S, et al. Complete loss of Fas ligand gene causes massive lymphoproliferation and early death, indicating a residual activity of gld allele. J Immunol 2004;172(4):2118-2125.
70. Hughes DE, Boyce BF. Apoptosis in bone physiology and disease. Mol Pathol 1997;50(3):132-137
71. Kincade PW, Medina KL, Smithson G. Sex hormones as negative regulators of lymphopoiesis. Immunol Rev 1994;137:119-134
72. Jilka RL, Hangoc G, Girasole G, et al. Increased osteoclast development after estrogen loss: mediation by interleukin-6. Science 1992;257(5066):88-91
73. Imai Y, Youn MY, Kondoh S, et al. Estrogens maintain bone mass by regulating expression of genes controlling function and life span in mature osteoclasts. Ann NY Acad Sci 2009;1173(Suppl 1):E31-9
74. Katavic V, Lukic IK, Kovacic N, et al. Increased bone mass is a part of the generalized lymphoproliferative disorder phenotype in the mouse. J Immunol 2003;170(3):1540-1547
75. Kovacic N, Grcevic D, Katavic V, et al. Fas receptor is required for estrogen deficiency-induced bone loss in mice. Lab Invest 2010;90(3):402-413
76. Goronzy JJ, Weyand CM. Developments in the scientific understanding of rheumatoid arthritis. Arthritis Res Ther 2009;11(5):249
77. Li X, Makarov SS. An essential role of NF-kappaB in the "tumor-like" phenotype of arthritic synoviocytes. Proc Natl Acad Sci USA 2006;103(46):17432-17437
78. Ratkay LG, Zhang L, Tonzetich J, Waterfield JD. Complete Freunds adjuvant induces an earlier and more severe arthritis in MRL-lpr mice. J Immunol 1993;151(9):5081-5087
79. Hoang TR, Hammermuller A, Mix E, et al. A proinflammatory role for Fas in joints of mice with collagen-induced arthritis. Arthritis Res Ther 2004;6(5):R404-14
80. Straus SE, Sneller M, Lenardo MJ, et al. An inherited disorder of lymphocyte apoptosis: the autoimmune lymphoproliferative syndrome. Ann Intern Med 1999;130(7):591-601
81. Siegel RM, Chan FK, Chun HJ, Lenardo MJ. The multifaceted role of Fas signaling in immune cell homeostasis and autoimmunity. Nat Immunol 2000;1(6):469-474
82. Eguchi K. Apoptosis in autoimmune diseases. Intern Med 2001;40(4):275-284
83. French LE, Tschopp J. Inhibition of death receptor signaling by FLICE-inhibitory protein as a mechanism for immune escape of tumors. J Exp Med 1999;190(7):891-894
84. Scholz M, Cinatl J. Fas/FasL interaction: a novel immune therapy approach with immobilized biologicals. Med Res Rev 2005;25(3):331-342
85. Sipos W, Pietschmann P, Rauner M. Strategies for novel therapeutic approaches targeting cytokines and signaling pathways of osteoclasto- and osteoblastogenesis in the fight against immune-mediated bone and joint diseases. Curr Med Chem 2008;15(2):127-136
86. Raisz LG. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest 2005;115(12):3318-3325
87. Weitzmann MN, Pacifici R. T cells: unexpected players in the bone loss induced by estrogen deficiency and in basal bone homeostasis. Ann NY Acad Sci 2007;1116:360-375
88. Garcia-Moreno C, Catalan MP, Ortiz A, et al. Modulation of survival in osteoblasts from postmenopausal women. Bone 2004;35(1):170-177.
89. Yamaza T, Miura Y, Bi Y, et al. Pharmacologic stem cell based intervention as a new approach to osteoporosis treatment in rodents. PLoS One 2008;3(7):e2615
90. Peng SL. Fas (CD95)-related apoptosis and rheumatoid arthritis. Rheumatology (Oxford) 2006;45(1):26-30
91. Du F, Wang L, Zhang Y, et al. Role of GADD45 beta in the regulation of synovial fluid T cell apoptosis in rheumatoid arthritis. Clin Immunol 2008;128(2):238-247
92. Szodoray P, Jellestad S, Nakken B, et al. Programmed cell death in rheumatoid arthritis peripheral blood T-cell subpopulations determined by laser scanning cytometry. Lab Invest 2003;83(12):1839-1848
93. Grcevic D, Jajic Z, Kovacic N, et al. Peripheral blood expression profiles of bone morphogenetic proteins, tumor necrosis factor-superfamily molecules, and transcription factor Runx2 could be used as markers of the form of arthritis, disease activity, and therapeutic responsiveness. J Rheumatol 2010;37(2):246-256
94. Telegina E, Reshetnyak T, Moshnikova A, et al. A possible role of Fas-ligand-mediated "reverse signaling" in pathogenesis of rheumatoid arthritis and systemic lupus erythematosus. Immunol Lett 2009;122(1):12-17
95. Smith MD, Walker JG. Apoptosis a relevant therapeutic target in rheumatoid arthritis? Rheumatology (Oxford) 2004;43(4):405-407
96. Hagimoto N, Kuwano K, Miyazaki H, et al. Induction of apoptosis and pulmonary fibrosis in mice in response to ligation of Fas antigen. Am J Respir Cell Mol Biol 1997;17(3):272-278
97. Ogasawara J, Watanabe-Fukunaga R, Adachi M, et al. Lethal effect of the anti-Fas antibody in mice. Nature 1993;364(6440):806-809
98. Carbone LD, Tylavsky FA, Cauley JA, et al. Association between bone mineral density and the use of nonsteroidal anti-inflammatory drugs and aspirin: impact of cyclooxygenase selectivity. J Bone Miner Res 2003;18(10):1795-1802
99. Catrina AI, Trollmo C, af Klint E, et al. Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: extended report. Arthritis Rheum 2005;52(1):61-72
100. Ohshima S, Mima T, Sasai M, et al. Tumour necrosis factor alpha (TNF-alpha) interferes with Fas-mediated apoptotic cell death on rheumatoid arthritis (RA) synovial cells: a possible mechanism of rheumatoid synovial hyperplasia and a clinical benefit of anti-TNF-alpha therapy for RA. Cytokine 2000;12(3):281-288
101. Wessels JA, Huizinga TW, Guchelaar HJ. Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis. Rheumatology (Oxford) 2008;47(3):249-255
102. ElOjeimy S, McKillop JC, El-Zawahry AM, et al. FasL gene therapy: a new therapeutic modality for head and neck cancer. Cancer Gene Ther 2006;13(8):739-745
103. Wesche-Soldato DE, Swan RZ, Chung CS, Ayala A. The apoptotic pathway as a therapeutic target in sepsis. Curr Drug Targets 2007;8(4):493-500
104. de Vries EG, Timmer T, Mulder NH, et al. Modulation of death receptor pathways in oncology. Drugs Today (Barc) 2003;39(Suppl C):95-109
105. Mocellin S. Targeting death receptors to fight cancer: from biological rational to clinical implementation. Curr Med Chem 2010;17(25):2713-2728
106. Garcia S, Liz M, Gomez-Reino JJ, Conde C. Akt activity protects rheumatoid synovial fibroblasts from Fas-induced apoptosis by inhibition of Bid cleavage. Arthritis Res Ther 2010;12(1):R33
107. Ducy P, Zhang R, Geoffroy V, et al. Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell 1997;89(5):747-754
108. Lavrik IN, Golks A, Krammer PH. Caspases: pharmacological manipulation of cell death. J Clin Invest 2005;115(10):2665-2672
109. Miura M, Chen XD, Allen MR, et al. A crucial role of caspase-3 in osteogenic differentiation of bone marrow stromal stem cells. J Clin Invest 2004;114(12):1704-1713
110. Takayanagi H. Mechanistic insight into osteoclast differentiation in osteoimmunology. J Mol Med 2005;83(3):170-179
111. Williams JP, Micoli K, McDonald JM. Calmodulin-an often-ignored signal in osteoclasts. Ann NY Acad Sci 2010;1192(1):358-364
112. Choi HJ, Park YR, Nepal M, et al. Inhibition of osteoclastogenic differentiation by Ikarisoside A in RAW 264.7 cells via JNK and NF-kappaB signaling pathways. Eur J Pharmacol 2010;636(1-3):28-35